Abbey Jenkins
Chief Executive Officer chez GAMIDA CELL LTD.
Fortune : 20 935 $ au 31/03/2024
Profil
Abigail L.
Jenkins is currently the President, Chief Executive Officer & Director at Gamida Cell Ltd.
She is also a Director at the Interstitial Cystitis Association of America, Inc., an Independent Director at Aquestive Therapeutics, Inc., and a Director at XORTX Therapeutics, Inc. Previously, Abigail held positions as the Senior Director-Marketing at Medimmune, Inc. in 2011, the Chief Commercial Officer & Head-US Business at Aquinox Pharmaceuticals, Inc., the Vice-President-Market Access at Relypsa, Inc. from 2014 to 2016, and the Vice President-Business Development at Allergan Ltd.
(Ireland) from 2011 to 2013.
She also served as the Chief Commercial & Business Officer at Lyndra Therapeutics, Inc. from 2021 to 2022.
Ms. Jenkins completed her undergraduate degree at Indiana University and her graduate degree at The Johns Hopkins University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GAMIDA CELL LTD.
0,44% | 15/03/2024 | 581 527 ( 0,44% ) | 20 935 $ | 31/03/2024 |
Postes actifs de Abbey Jenkins
| Sociétés | Poste | Début |
|---|---|---|
| GAMIDA CELL LTD. | Chief Executive Officer | 17/09/2022 |
| AQUESTIVE THERAPEUTICS, INC. | Director/Board Member | 01/04/2024 |
| XORTX THERAPEUTICS INC. | Director/Board Member | 08/04/2024 |
| Interstitial Cystitis Association of America, Inc. | Director/Board Member | - |
Anciens postes connus de Abbey Jenkins
| Sociétés | Poste | Fin |
|---|---|---|
Lyndra Therapeutics, Inc.
 Lyndra Therapeutics, Inc. Packaged SoftwareTechnology Services Lyndra Therapeutics, Inc. develops software technology for oral drug formulations. It offers pharmacology, therapeutic impact, reduced pill burden, and reduced care giver burden. The company was founded by Amy W. Schulman, Carlo Giovanni Traverso, Andrew Bellinger, and Robert S. Langer Jr. in 2015 and is headquartered in Watertown, MA. | Corporate Officer/Principal | 01/08/2022 |
| RELYPSA INC | Corporate Officer/Principal | 01/05/2016 |
| ALLERGAN PLC | Corporate Officer/Principal | 01/09/2013 |
| Medimmune, Inc. | Sales & Marketing | 01/09/2011 |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
Formation de Abbey Jenkins
| Indiana University | Undergraduate Degree |
| The Johns Hopkins University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AQUESTIVE THERAPEUTICS, INC. | Health Technology |
| GAMIDA CELL LTD. | Health Technology |
| XORTX THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
| Interstitial Cystitis Association of America, Inc. | |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
| Medimmune, Inc. | Health Technology |
Lyndra Therapeutics, Inc.
Lyndra Therapeutics, Inc. Packaged SoftwareTechnology Services Lyndra Therapeutics, Inc. develops software technology for oral drug formulations. It offers pharmacology, therapeutic impact, reduced pill burden, and reduced care giver burden. The company was founded by Amy W. Schulman, Carlo Giovanni Traverso, Andrew Bellinger, and Robert S. Langer Jr. in 2015 and is headquartered in Watertown, MA. | Technology Services |
